Adocia is a biotechnology company specialized in the development of best-in-class medicines from already approved therapeutic proteins. Through its BioChaperone technological platform, Adocia enhances the effectiveness and safety of therapeutic proteins and their ease of use for patients. The Company has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies. In this field, ADOCIA is engaged in collaborative programs with major pharmaceutical companies.